Novel effects other than antisecretory action and off-label use of proton pump inhibitors

被引:19
作者
Suzuki, H [1 ]
Hibi, T [1 ]
机构
[1] Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, Tokyo 1608582, Japan
基金
日本学术振兴会;
关键词
D O I
10.1517/14656566.6.1.59
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The proton pump inhibitors (PPIs) are a relatively new class of agents used for the treatment of acid-related disorders, including peptic ulcer diseases, reflux oesophagitis and Zollinger-Ellison syndrome, and in enhancing antibiotic therapy in the eradication of Helicobacter pylori in patients with peptic ulcer disease. The PPIs are the most potent gastric acid-suppressing agents currently in clinical use. According to the recent basic study, PPIs may act not only as potent acid suppressants, but also as anti-inflammatory or pro-regenerative agents. On the other hand, in the clinical field, general practitioners still tend to prescribe PPIs for unlicensed indications, such as non-ulcer dyspepsia and nonspecific abdominal pain. This article reviews the novel pharmacological action other than acid secretion and the diverse clinical usage of PPIs, in order to seek possible extensions of the use of this unique agent.
引用
收藏
页码:59 / 67
页数:9
相关论文
共 55 条
[1]   Symptomatic response to Helicobacter pylori eradication in children with recurrent abdominal pain:: Double blind randomized placebo-controlled trial [J].
Ashorn, M ;
Rägö, T ;
Kokkonen, J ;
Ruuska, T ;
Rautelin, H ;
Karikoski, R .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2004, 38 (08) :646-650
[2]  
Bashford JNR, 1998, BRIT MED J, V317, P452
[3]   Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia [J].
Blum, AL ;
Talley, NJ ;
O'Moráin, C ;
van Zanten, SV ;
Labenz, J ;
Stolte, M ;
Louw, JA ;
Stubberöd, A ;
Theodórs, A ;
Sundin, M ;
Bolling-Sternevald, E ;
Junghard, O .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (26) :1875-1881
[4]   STRUCTURE ACTIVITY RELATIONSHIPS OF SUBSTITUTED BENZIMIDAZOLES [J].
BRANDSTROM, A ;
LINDBERG, P ;
JUNGGREN, U .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1985, 20 :15-22
[5]   IS OMEPRAZOLE HELPFUL IN INFLAMMATORY BOWEL-DISEASE [J].
DICKINSON, JB .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1994, 18 (04) :317-319
[6]   In-vitro activity of lansoprazole against Helicobacter pylori [J].
Figura, N ;
Crabtree, JE ;
Dattilo, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (05) :585-590
[7]   Therapeutic choices in reflux disease: Defining the criteria for selecting a proton pump inhibitor [J].
Freston, JW .
AMERICAN JOURNAL OF MEDICINE, 2004, 117 :14S-22S
[8]   EFFECTS OF LANSOPRAZOLE ON ETHANOL-INDUCED INJURY AND PG SYNTHETIC ACTIVITY IN RAT GASTRIC-MUCOSA [J].
FUKUDA, T ;
ARAKAWA, T ;
SHIMIZU, Y ;
OHTANI, K ;
HIGUCHI, K ;
KOBAYASHI, K .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1995, 20 :S5-S7
[9]   Gastroesophageal reflux disease: Could intervention in childhood reduce the risk of later complications? [J].
Gold, BD .
AMERICAN JOURNAL OF MEDICINE, 2004, 117 :23S-29S
[10]   Early events in proton pump inhibitor-associated exacerbation of corpus gastritis [J].
Graham, DY ;
Opekun, AR ;
Yamaoka, Y ;
Osato, MS ;
El-Zimaity, HMT .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (02) :193-200